Mita, Monica
Fu, Siqing
Piha-Paul, Sarina Anne
Janku, Filip
Mita, Alain
Natale, Ronald
Guo, Wei
Zhao, Charles
Kurzrock, Razelle
Naing, Aung
Funding for this research was provided by:
Merck KGaA, Darmstadt, Germany
EMD Serono Inc., Billerica, US
Article History
Received: 5 December 2016
Accepted: 3 February 2017
First Online: 13 February 2017
Compliance with ethical standards
:
: M Mita has no conflicts of interest to declare.S Fu has no conflicts of interest to declare.SA Piha-Paul has no conflicts of interest to declare.F Janku has no conflicts of interest to declare.A Mita has no conflicts of interest to declare.R Natale has no conflicts of interest to declare.W Guo was an employee of EMD Serono Inc, Billerica, USA who sponsored this trial.C Zhao is an employee of EMD Serono Inc., Billerica, USA who sponsored this trial.R Kurzrock has research funding from Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, and Guardant, as well as consultant/advisory board fees from Sequenom, Actuate Therapeutics, and Xbiotech, and an ownership interest in Novena, Inc. and Curematch, Inc.A Naing has no conflicts of interest to declare.
: This study was sponsored by Merck KGaA, Darmstadt, Germany and EMD Serono Inc., Billerica, USA.
: Written informed consent was obtained from all patients prior to study initiation. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institution of the participating centers and with the 1964 Helsinki declaration and its later amendments.